Pallas Capital Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Pallas Capital Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,338	Closed	-$89.8K	–	866
2025 Q4	$89.8K	Sell	17,338 -7	-0%	-$36	﹤0.01%	846
2025 Q3	$90.5K	Sell	17,345 -417	-2%	-$2.17K	﹤0.01%	829
2025 Q2	$68K	Buy	+17,762	New	+$45.9K	﹤0.01%	815

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pallas Capital Advisors's ALDX Position: Q1 2026 in Review

Pallas Capital Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 17,338 shares — an estimated $89.8K sold.

Pallas Capital Advisors first reported a position in ALDX in Q2 2025 and held it in 3 quarters. The position peaked at $90.5K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

Pallas Capital Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
Pallas Capital Advisors sold 17,338 Aldeyra Therapeutics shares in Q1 2026, an estimated $89.8K.
Pallas Capital Advisors first reported a position in Aldeyra Therapeutics in Q2 2025 and held it in 3 quarters.
Pallas Capital Advisors's Aldeyra Therapeutics position peaked at $90.5K in Q3 2025.
126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.